Literature DB >> 3063167

Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B.

M Debono1, B J Abbott, J R Turner, L C Howard, R S Gordee, A S Hunt, M Barnhart, R M Molloy, K E Willard, D Fukuda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3063167     DOI： 10.1111/j.1749-6632.1988.tb40398.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  15 in total

Review 1.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 2.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Use of Saccharomyces cerevisiae expressing beta-galactosidase to screen for antimycotic agents directed against yeast cell wall biosynthesis and possible application to pathogenic fungi.

Authors:  P G Zaworski; G S Gill
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

4.  Deacylation of Echinocandin B by Streptomyces species: a novel method for the production of Echinocandin B nucleus.

Authors:  M C Shivakumar; S Manohar; B Ishwar; P Raghu; J Savitha
Journal:  3 Biotech       Date:  2019-10-23       Impact factor: 2.406

5.  Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains.

Authors:  Lei Shao; Jian Li; Aijuan Liu; Qing Chang; Huimin Lin; Daijie Chen
Journal:  Appl Environ Microbiol       Date:  2012-12-07       Impact factor: 4.792

6.  Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.

Authors:  T J Walsh; J W Lee; P Kelly; J Bacher; J Lecciones; V Thomas; C Lyman; D Coleman; R Gordee; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis.

Authors:  M B Kurtz; C Douglas; J Marrinan; K Nollstadt; J Onishi; S Dreikorn; J Milligan; S Mandala; J Thompson; J M Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Use of cilofungin as direct fluorescent probe for monitoring antifungal drug-membrane interaction.

Authors:  Y T Ko; R D Ludescher; D J Frost; B P Wasserman
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 9.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

10.  In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.

Authors:  K Bartizal; G Abruzzo; C Trainor; D Krupa; K Nollstadt; D Schmatz; R Schwartz; M Hammond; J Balkovec; F Vanmiddlesworth
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.